论文部分内容阅读
目的:探讨利用CRP联合CA125、CEA对卵巢癌诊断的价值。方法:采用回顾式分析方式,从2013年1月至2015年5月来我院进行卵巢癌症诊断的患者病例当中选出三组对象,其中诊断为卵巢癌的共75例,作为癌症组;诊断出女性盆腔良性疾病的患者共29例,作为疾病组;选出诊断为健康的研究对象共68例,作为对比组。分别抽取三组研究对象的血液进行检查,了解其血液当中C反应蛋白(CRP)、糖类抗原CA125(CA125)、癌胚抗原(CEA)的浓度。结果:本次研究中,癌症组患者的C反应蛋白、糖类抗原CA125、癌胚抗原的含量分别为(24.68±12.21)、(291.27±122.16)、(8.71±6.44),明显高于疾病组和对比组。三组数据之间存在明显差异,具有统计学意义(P<0.05)。结论:在临床诊断卵巢癌时,患者的C反应蛋白(CRP)、糖类抗原CA125(CA125)、癌胚抗原(CEA)的浓度较其它疾病和正常人要明显增高,因此具有诊断意义,能够作为卵巢癌诊断的指导数据。
Objective: To explore the use of CRP combined with CA125, CEA in the diagnosis of ovarian cancer. METHODS: A retrospective analysis was performed to select three groups of patients from January 2013 to May 2015 in our hospital for ovarian cancer diagnosis. Among them, 75 cases were diagnosed as ovarian cancer and were diagnosed as cancer group A total of 29 women with pelvic benign disease were selected as the disease group. Sixty-eight healthy subjects were selected as the control group. The blood of three groups of subjects were drawn to examine the blood levels of C-reactive protein (CRP), carbohydrate antigen CA125 (CA125) and carcinoembryonic antigen (CEA). Results: In this study, the levels of C-reactive protein, carbohydrate antigen CA125 and carcinoembryonic antigen in patients with cancer were (24.68 ± 12.21) and (291.27 ± 122.16) and (8.71 ± 6.44) respectively, which were significantly higher than those in the disease group And control group. There was a significant difference between the three groups of data, with statistical significance (P <0.05). CONCLUSIONS: The levels of C-reactive protein (CRP), carbohydrate antigen CA125 (CA125) and carcinoembryonic antigen (CEA) in patients with clinically diagnosed ovarian cancer are significantly higher than those in other diseases and normal subjects and are therefore of diagnostic value As a guideline for the diagnosis of ovarian cancer.